|
US6365787B1
(en)
|
1994-09-30 |
2002-04-02 |
The Johns Hopkins University |
Compounds for the suppression of HIV TAT transactivation
|
|
AU736587B2
(en)
*
|
1996-11-20 |
2001-08-02 |
Yale University |
Survivin, a protein that inhibits cellular apoptosis, and its modulation
|
|
US7226730B1
(en)
*
|
1997-02-26 |
2007-06-05 |
The General Hospital Corporation |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
|
|
CA2282729A1
(en)
*
|
1997-02-26 |
1998-09-03 |
The General Hospital Corporation |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
|
|
US20030033621A1
(en)
*
|
1997-02-26 |
2003-02-13 |
De La Monte Suzanne |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
|
|
US6346389B1
(en)
|
1998-04-01 |
2002-02-12 |
Yale University |
Method for selectively modulating the interactions between survivin and tubulin
|
|
WO2000003693A1
(en)
*
|
1998-07-14 |
2000-01-27 |
Jenner Biotherapies, Inc. |
Survivin, and peptides thereof, as an anti-cancer vaccine
|
|
US6077709A
(en)
*
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
|
AU2003205017B2
(en)
*
|
1998-09-29 |
2005-12-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of survivin expression
|
|
US6838283B2
(en)
|
1998-09-29 |
2005-01-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of survivin expression
|
|
US6335194B1
(en)
*
|
1998-09-29 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of survivin expression
|
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
|
US6608108B2
(en)
*
|
1999-10-15 |
2003-08-19 |
Johns Hopkins University |
Method for treatment of tumors using nordihydroguaiaretic acid derivatives
|
|
PT1234031T
(pt)
|
1999-11-30 |
2017-06-26 |
Mayo Foundation |
B7-h1, uma nova molécula imunoregulatória
|
|
AU784884B2
(en)
*
|
1999-12-10 |
2006-07-20 |
Anticancer, Inc. |
Methods for introducing genes into mammalian subjects
|
|
US6509162B1
(en)
|
2000-02-29 |
2003-01-21 |
Yale University |
Methods for selectively modulating survivin apoptosis pathways
|
|
WO2002002622A2
(en)
*
|
2000-06-29 |
2002-01-10 |
The Salk Institute For Biological Studies |
Crystal structure of survivin
|
|
WO2002057787A2
(en)
*
|
2001-01-12 |
2002-07-25 |
Yale University |
Detection of survivin in the biological fluids of cancer patients
|
|
US7776518B2
(en)
|
2001-01-12 |
2010-08-17 |
Yale University |
Detection of survivin in the biological fluids of cancer patients
|
|
DE10102722A1
(de)
*
|
2001-01-22 |
2002-08-14 |
Medinnova Ges Med Innovationen |
Verfahren und Testsystem zum Auffinden von Nervenzell-schützenden Substanzen
|
|
WO2003061519A2
(en)
*
|
2002-01-18 |
2003-07-31 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for preserving the viability of photoreceptor cells
|
|
US7892559B2
(en)
|
2002-01-30 |
2011-02-22 |
Survac Aps |
Survivin-derived peptides and use thereof
|
|
US20040210035A1
(en)
*
|
2002-01-30 |
2004-10-21 |
Straten Eivind Per Thor |
Survivin-derived peptides and use thereof
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US7332580B2
(en)
*
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20040102395A1
(en)
*
|
2002-11-22 |
2004-05-27 |
Isis Pharmaceuticals Inc. |
Modulation of IAP-like expression
|
|
JP4606879B2
(ja)
*
|
2002-11-15 |
2011-01-05 |
ジェノミック ヘルス， インコーポレイテッド |
Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
|
|
US20080194491A1
(en)
*
|
2002-12-24 |
2008-08-14 |
Stewart Duncan J |
Methods of Diagnosing, Preventing, and Treating Early Onset of Pulmonary Hypertension
|
|
US20040231909A1
(en)
|
2003-01-15 |
2004-11-25 |
Tai-Yang Luh |
Motorized vehicle having forward and backward differential structure
|
|
DK2359841T3
(en)
|
2003-01-30 |
2015-02-02 |
Survac Aps |
Survivin-derived peptides and the use thereof
|
|
AU2004211955B2
(en)
*
|
2003-02-06 |
2009-05-14 |
Cedars-Sinai Medical Center |
Gene expression markers for response to EGFR inhibitor drugs
|
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
|
EP1597391B1
(en)
*
|
2003-02-20 |
2008-10-29 |
Genomic Health, Inc. |
Use of intronic rna to measure gene expression
|
|
MXPA05010255A
(es)
*
|
2003-03-24 |
2005-12-14 |
Scripps Research Inst |
Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas.
|
|
CA2527321A1
(en)
*
|
2003-05-30 |
2004-12-23 |
Genomic Health, Inc. |
Gene expression markers for response to egfr inhibitor drugs
|
|
WO2005002507A2
(en)
*
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
|
CA2530738C
(en)
|
2003-06-24 |
2020-01-21 |
Genomic Health, Inc. |
Prediction of likelihood of cancer recurrence
|
|
EP3330875B1
(en)
|
2003-07-10 |
2021-12-01 |
Genomic Health, Inc. |
Expression profile algorithm and test for prognosing breast cancer recurrence
|
|
EP1678327A4
(en)
*
|
2003-10-16 |
2007-10-10 |
Genomic Health Inc |
QRT-PCR TEST SYSTEM FOR GENE EXPRESSION PROFILING
|
|
ES2323588T3
(es)
|
2003-11-19 |
2009-07-21 |
Merck Patent Gmbh |
Proteinas que pertenecen a la familia bcl-2 y fragmentos de las mismas, y su uso en pacientes con cancer.
|
|
EP1699936B1
(en)
*
|
2003-12-23 |
2011-02-09 |
Genomic Health, Inc. |
Universal amplification of fragmented rna
|
|
US7871769B2
(en)
|
2004-04-09 |
2011-01-18 |
Genomic Health, Inc. |
Gene expression markers for predicting response to chemotherapy
|
|
US20050260659A1
(en)
*
|
2004-04-23 |
2005-11-24 |
Exagen Diagnostics, Inc. |
Compositions and methods for breast cancer prognosis
|
|
US7342093B2
(en)
*
|
2004-07-23 |
2008-03-11 |
University Of Massachusetts |
Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
|
|
PL3428191T3
(pl)
|
2004-10-06 |
2025-04-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
|
|
AU2005304824B2
(en)
|
2004-11-05 |
2011-12-22 |
Genomic Health, Inc. |
Predicting response to chemotherapy using gene expression markers
|
|
ES2384107T3
(es)
*
|
2004-11-05 |
2012-06-29 |
Genomic Health, Inc. |
Indicadores moleculares de pronóstico de cáncer de mama y predicción de la respuesta al tratamiento
|
|
AU2005304110B2
(en)
|
2004-11-09 |
2009-06-11 |
Enzon Pharmaceuticals, Inc. |
LNA oligonucleotides and the treatment of cancer
|
|
DE602005012137D1
(de)
*
|
2004-11-12 |
2009-02-12 |
Life Sciences Res Partners Vzw |
Verwendung von survivin zur behandlung von niereninsuffizienz
|
|
MX2007007624A
(es)
*
|
2004-12-22 |
2007-08-03 |
Gillette Co |
Reduccion del crecimiento del pelo con inhibidores de survivina.
|
|
CA2593714C
(en)
|
2005-02-04 |
2013-09-10 |
Survac Aps |
Survivin peptide vaccine
|
|
WO2006091666A2
(en)
*
|
2005-02-23 |
2006-08-31 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating conditions of the eye
|
|
US20060276423A1
(en)
*
|
2005-04-18 |
2006-12-07 |
Rachel Altura |
Survivin-directed RNA interference-compositions and methods
|
|
WO2006125117A2
(en)
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
|
|
US7272013B1
(en)
*
|
2005-07-28 |
2007-09-18 |
American Megatrends, Inc. |
Interchangeable design support system
|
|
US7592330B2
(en)
*
|
2005-08-08 |
2009-09-22 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for preserving the viability of photoreceptor cells
|
|
US20070049752A1
(en)
*
|
2005-08-23 |
2007-03-01 |
Drysdale Neville E |
Preparation of 2,6-dioxa-7-aza-bicyclo[2.2.2] octanes
|
|
US7812173B2
(en)
*
|
2005-08-23 |
2010-10-12 |
E.I. Du Pont De Nemours And Company |
Tetrahydro-1,8-dioxa-4a-aza-naphthalenes in coating applications
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
WO2007082144A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
|
US20090215084A1
(en)
*
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
|
AU2007353412A1
(en)
*
|
2006-11-21 |
2008-11-20 |
Fox Chase Cancer Center |
Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
|
|
US8002827B2
(en)
*
|
2007-04-24 |
2011-08-23 |
Abbott Medical Optics Inc. |
Systems and methods for ocular measurements
|
|
US8974526B2
(en)
|
2007-08-27 |
2015-03-10 |
Amo Groningen B.V. |
Multizonal lens with extended depth of focus
|
|
US9216080B2
(en)
|
2007-08-27 |
2015-12-22 |
Amo Groningen B.V. |
Toric lens with decreased sensitivity to cylinder power and rotation and method of using the same
|
|
EP2200653A2
(en)
|
2007-09-10 |
2010-06-30 |
University of Massachusetts |
Mitochondria-targeted anti-tumour agents
|
|
ATE523810T1
(de)
|
2008-02-15 |
2011-09-15 |
Amo Regional Holdings |
System, brillenglas und verfahren zur erweiterung der fokustiefe
|
|
US8439498B2
(en)
|
2008-02-21 |
2013-05-14 |
Abbott Medical Optics Inc. |
Toric intraocular lens with modified power characteristics
|
|
US20110020325A1
(en)
*
|
2008-02-29 |
2011-01-27 |
Kwon Eugene D |
Methods for reducing granulomatous inflammation
|
|
EP2270144B8
(en)
*
|
2008-03-31 |
2017-08-30 |
tella Inc. |
Partial peptide of survivin presented on mhc class ii molecule and use thereof
|
|
US8862447B2
(en)
|
2010-04-30 |
2014-10-14 |
Amo Groningen B.V. |
Apparatus, system and method for predictive modeling to design, evaluate and optimize ophthalmic lenses
|
|
EP3954327B1
(en)
|
2009-12-18 |
2025-02-19 |
AMO Groningen B.V. |
Single microstructure lens
|
|
EP2560629B1
(en)
|
2010-04-23 |
2020-06-03 |
Massachusetts Eye & Ear Infirmary |
Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
|
|
WO2012061045A2
(en)
|
2010-11-01 |
2012-05-10 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for preserving retinal ganglion cells
|
|
CA2819629A1
(en)
|
2010-12-01 |
2012-06-07 |
Amo Groningen B.V. |
A multifocal lens having an optical add power progression, and a system and method of providing same
|
|
WO2013059791A2
(en)
|
2011-10-21 |
2013-04-25 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for promoting axon regeneration and nerve function
|
|
CA2877203A1
(en)
|
2012-12-04 |
2014-06-12 |
Amo Groningen B.V. |
Lenses, systems and methods for providing binocular customized treatments to correct presbyopia
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
ES2702622T3
(es)
|
2013-03-27 |
2019-03-04 |
Immunovaccine Technologies Inc |
Método para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer
|
|
EP3052131B1
(en)
|
2013-10-01 |
2018-12-05 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
|
JP2017501172A
(ja)
*
|
2013-12-16 |
2017-01-12 |
メルク パテント ゲーエムベーハー |
サバイビン指向性癌ワクチン治療
|
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
|
EP3171896A4
(en)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
|
CA2972635A1
(en)
|
2015-01-06 |
2016-07-14 |
Immunovaccine Technologies Inc. |
Lipid a mimics, methods of preparation, and uses thereof
|
|
EP3291842A4
(en)
|
2015-05-07 |
2019-01-23 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
SURVIVIN VACCINE VARIANT FOR THE TREATMENT OF CANCER
|
|
EP3344287B1
(en)
*
|
2015-09-04 |
2021-05-26 |
Health Research, Inc. |
Anti-survivin antibodies for cancer therapy
|
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
|
EP3377099A4
(en)
|
2015-11-18 |
2019-07-24 |
ImmunoVaccine Technologies Inc. |
ADJUVANT SYSTEMS AND WATER-FREE VAPOR COMPOSITION OF ONE POLYI: C-POLYNUCLEOTIDADJUVANS AND ADJUVANS ON LIPID BASE
|
|
WO2017137841A1
(en)
|
2016-02-09 |
2017-08-17 |
Amo Groningen B.V. |
Progressive power intraocular lens, and methods of use and manufacture
|
|
CA3018558C
(en)
|
2016-03-23 |
2025-06-10 |
Johnson & Johnson Surgical Vision, Inc. |
OPHTHALMIC APPARATUS WITH CORRECTIVE MERIDIANS FEATURING AN EXTENDED TOLERANCE BANDS BY MODIFYING REFRACTIVE POWERS IN A UNIFORM MERIDIAN DISTRIBUTION
|
|
US11123178B2
(en)
|
2016-03-23 |
2021-09-21 |
Johnson & Johnson Surgical Vision, Inc. |
Power calculator for an ophthalmic apparatus with corrective meridians having extended tolerance or operation band
|
|
US11060087B2
(en)
*
|
2016-06-15 |
2021-07-13 |
The Regents Of The University Of California |
Synthetic promoters for high throughput screening and gene modulation
|
|
US11013594B2
(en)
|
2016-10-25 |
2021-05-25 |
Amo Groningen B.V. |
Realistic eye models to design and evaluate intraocular lenses for a large field of view
|
|
US10739227B2
(en)
|
2017-03-23 |
2020-08-11 |
Johnson & Johnson Surgical Vision, Inc. |
Methods and systems for measuring image quality
|
|
EP3687447A1
(en)
|
2017-11-30 |
2020-08-05 |
AMO Groningen B.V. |
Intraocular lenses that improve post-surgical spectacle independent and methods of manufacturing thereof
|
|
FR3087448B1
(fr)
|
2018-10-23 |
2023-10-13 |
Pdc Line Pharma |
Lignee pdc modifiee pour secreter une cytokine
|
|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
EP3873500A4
(en)
|
2018-10-31 |
2023-01-11 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
US11886046B2
(en)
|
2019-12-30 |
2024-01-30 |
Amo Groningen B.V. |
Multi-region refractive lenses for vision treatment
|
|
WO2022233683A1
(en)
|
2021-05-05 |
2022-11-10 |
Amo Groningen B.V. |
Ring halometer system and method for quantifying dysphotopsias
|